<DOC>
	<DOCNO>NCT00944372</DOCNO>
	<brief_summary>The objective study evaluate effect age ( geriatric ) renal function safety , efficacy pharmacokinetics OctreoScan recommend clinical dose patient population .</brief_summary>
	<brief_title>Study Evaluate Effect Age ( Geriatric ) Kidney Function Safety , Efficacy Pharmacokinetics OctreoScan Patients Who Have New Recurrent Tumors</brief_title>
	<detailed_description />
	<mesh_term>Somatostatin</mesh_term>
	<criteria>1 . Males females 18 year age old . 2 . If female childbearing potential , patient must negative pregnancy test within 24 hour study drug administration . In addition , female patient childbearing potential must agree use medically accept method contraception throughout study . 3 . If deem necessary Principal Investigator , patient enter pharmacokinetic population must willing house within investigational facility minimum 24 hour follow drug administration . 4 . Patients ( able ) legally authorize representative must ability understand requirement study provide write consent participate agree abide study requirement . 5 . Patients must tumor localization conventional imaging method prior enrollment ( i.e. , CT , MRI , US , angiogram ) . 6 . Patients refer scintigraphy solid tumor high suspicion contain somatostatin receptor positive tissue . 7 . Patients firsttime tumor must schedule tissue biopsy . A tissue sample send core laboratory conventional histology immunohistochemistry analysis . 8 . Patients recurrent tumor progressive tumor must previous biopsy result document , previous biopsy tissue obtainable immunohistochemistry analysis . 1 . Patients receive Sandostatin LAR &lt; 21 day prior dose Sandostatin Immediate Release ( IM ) &lt; 24 hour prior dose . 2 . Patients receive investigational drug within 30 day admission study plan participate clinical study prior end study 's monitoring period ( patient research protocol use approve drug accept ) . 3 . Patients pregnant , breastfeed lactating . 4 . Patients medical condition , serious intercurrent illness , extenuate circumstance would significantly decrease study compliance , include prescribe followup . 5 . Patients schedule undergo scintigraphy within 7 day prior study participation PET scan within 24 hour prior study participation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Tumor</keyword>
	<keyword>somatostatin receptor</keyword>
</DOC>